Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study
Alimentary Pharmacology & Therapeutics · 2026-05 · 63 (10) · 1410-1420
DOI: 10.1111/apt.70574 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 18.02.2026. Verfasst von Mariko Maxwell und 5 weiteren Autor:innen. Beteiligte Einrichtung: Section of Digestive Diseases and Liver Center, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Fenofibrate, Liver Cirrhosis, Biliary, Hypolipidemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Nearly 40% of patients with primary biliary cholangitis (PBC) have an incomplete response to first‐line ursodeoxycholic acid (UDCA) therapy. Fenofibrate, a peroxisome proliferator‐activated receptor alpha (PPAR‐α) agonist, is an effective second‐line treatment for PBC. Compared to the recently FDA‐approved PPAR agonists, fenofibrate may provide a more cost‐effective and accessible alternative. However, longitudinal data on fenofibrate use in PBC are lacking. Here, we review our experience using fenofibrate in PBC and its long‐term effects on cholestatic biomarkers, prognostic scores, and fibrosis indices. Approach and Results This single‐centre retrospective cohort study examined PBC patients prescribed fenofibrate between 2012 and 2024 for persistent elevations in alkaline phosphatase (ALP) despite UDCA therapy. The study included 59 patients treated with fenofibrate for a mean duration of 44.8 months. The overall median time to ALP normalisation was 9.5 months. Of those who did not meet Paris II criteria prior to fenofibrate therapy, the median time to ALP normalisation was 11.2 months. GLOBE prognostic scores significantly improved with fenofibrate therapy, while UK‐PBC scores and fibrosis index scores (FIB‐4) remained stable. Fenofibrate was well‐tolerated by most patients, with only 5% of patients discontinuing therapy due to elevated liver enzymes. Conclusions In this long‐term cohort of PBC patients with insufficient response to UDCA, fenofibrate significantly improved cholestatic markers and prognostic scores over time. Given this, and its favourable safety profile, fenofibrate should be further considered as an accessible and affordable second‐line therapy in PBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Digestive Diseases and Liver Center, Yale School of Medicine, New Haven, Connecticut, USA.
- Yale School of Public Health, New Haven, Connecticut, USA.
ORCID-Profile: Mariko Maxwell, James L Boyer, David N Assis
Zitieren
APA
Maxwell, M., Deng, Y., Chen, B., Silveira, M. G., Boyer, J. L., & Assis, D. N. (2026). Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study. Alimentary Pharmacology & Therapeutics, 63(10), 1410-1420. https://doi.org/10.1111/apt.70574
Vancouver
Maxwell M, Deng Y, Chen B, Silveira MG, Boyer JL, Assis DN. Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study. Alimentary Pharmacology & Therapeutics. 2026;63(10):1410-1420. doi:10.1111/apt.70574
BibTeX
@article{Maxwell2026,
author = {Maxwell, Mariko and Deng, Yanhong and Chen, Bonnie and Silveira, Marina G and Boyer, James L and Assis, David N},
title = {Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {63},
number = {10},
pages = {1410--1420},
doi = {10.1111/apt.70574}
}
EUVIMED